Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination
Abstract Background Eliminating hepatitis C virus (HCV) infections is a goal set by the World Health Organization. This has become possible with the introduction of highly effective and safe direct-acting antivirals (DAA) but limitations remain due to undiagnosed HCV infections and loss of patients...
Saved in:
| Main Authors: | Dorota Zarębska-Michaluk, Michał Brzdęk, Olga Tronina, Justyna Janocha-Litwin, Marek Sitko, Anna Piekarska, Jakub Klapaczyński, Anna Parfieniuk-Kowerda, Barbara Sobala-Szczygieł, Magdalena Tudrujek-Zdunek, Łukasz Laurans, Robert Flisiak |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-10-01
|
| Series: | BMC Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12916-024-03699-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination
by: Dorota Zarębska-Michaluk, et al.
Published: (2024-11-01) -
Treatment of HCV infection in patients with steatotic liver disease
by: Robert Flisiak, et al.
Published: (2024-07-01) -
Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Aleksandra Berkan-Kawińska, et al.
Published: (2024-07-01) -
Cardiac toxicity associated with HCV direct antiviral agents
by: Claudio Ucciferri, et al.
Published: (2018-10-01) -
Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years
by: Pietro Torre, et al.
Published: (2024-11-01)